Business
Publication of FY22 Annual Report
Publication of FY22 Annual Report.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n 3 March 2023 \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n \n (\n \n \"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \n \n \n \n \n \n \n Publication of 2022 Annual Report\n \n \n \n \n \n Oxford BioDynamics Plc (AIM: OBD),\n a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch\n ®\n 3D genomics platform\n , today announces that copies of its annual report and accounts for the year ended 30 September 2022 (incorporating the Notice of Annual General Meeting) (\"Annual Report\") have been posted to shareholders. An electronic copy of the Annual Report will be\n available on its website at www.oxfordbiodynamics.com/investors/financial-results.\n \n \n As stated in the recent Full Year results announcement, the Company's Annual General Meeting will be held at 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, on 30 March 2023 at 12.00pm.\n \n \n -Ends-\n \n \n \n \n \n \n \n \n For further details please contact:\n \n \n \n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n Jon Burrows, CEO\n \n \n Paul Stockdale, CFO\n \n \n \n \n \n \n \n +44 (0)1865 518910\n \n \n \n \n \n \n \n Shore Capital\n \n \n \n \n Nominated Adviser and Broker\n \n \n \n Stephane Auton\n \n \n John More\n \n \n \n \n \n \n \n +44 (0)20 7408 4090\n \n \n \n \n \n \n Instinctif Partners\n \n \n \n \n Tel: +44 (0)20 7457 2020\n \n \n \n \n \n \n Melanie Toyne-Sewell / Rozi Morris\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n Notes for Editors\n \n \n \n \n \n \n \n \n \n About Oxford BioDynamics Plc\n \n \n \n Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.\n \n \n Its flagship product is\n \n \n EpiSwitch® CiRT\n \n \n (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.\n \n \n In March 2021, the Company launched its first commercial prognostic test,\n \n \n EpiSwitch\n \n \n ®\n \n \n \n CST\n \n \n (Covid Severity Test) and the first commercially available microarray kit for high-reso...